Trial Profile

A Phase II Trial of Cediranib in the Treatment of Patients With Alveolar Soft Part Sarcoma (CASPS)

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 06 Sep 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cediranib (Primary)
Indications Alveolar soft part sarcoma
Focus Therapeutic Use
Acronyms CASPS

Most Recent Events

16 Oct 2019 Results presented in The Institute of Cancer Research media release.
31 May 2019 Results assessing safety of cediranib in alveolar soft-part sarcoma patients, published in the Lancet Oncology.
22 Jan 2019 Planned End Date changed from 29 Jul 2018 to 1 Jan 2020.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com